Advertisement

Progress Report on a Phase II Trial of 5-Fluorouracil Plus Citrovorum Factor in Women with Metastatic Breast Cancer

  • C. L. Loprinzi
  • J. N. Ingle
  • D. J. Schaid
  • J. C. Buckner
  • J. H. Edmonson
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 131)

Abstract

5-fluorouracil (FUra) has definite, albeit limited, antitumor activity against breast carcinoma (1). Inhibition of the enzyme, thymidylate synthetase (TS) by FdUMP, an active FUra metabolite, has been postulated as one biochemical mechanism for this antitumor activity (2). TS inhibition is markedly augmented by the presence of increased concentrations of the reduced folate, citrovorum factor (CF) (3). In 1985, preliminary information suggested that FUra plus CF resulted in more substantial activity against heavily pretreated metastatic breast cancer than would have been expected with FUra alone (4). This current study was designed 1) to study the antitumor activity and toxicity of FUra plus CF in metastatic breast cancer patients who had not been “heavily pretreated” with chemotherapy, 2) to examine the impact of this regimen on tumor TS activity, and 3) to correlate the degree of TS inhibition with clinical outcome. The protocol continues to accrue patients and this communication provides a progress report relating to antitumor activity and toxicity.

Keywords

Metastatic Breast Cancer Folinic Acid Metastatic Breast Cancer Patient Thymidylate Synthetase Skin Hyperpigmentation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S. Hellman, J. Harris, GP Canellos, et al, 1982, Principals and Practice of Oncology, in: “Cancer”, V. DeVita, S. Hellman, and S. Rosenberg, ed., J.B. Lippincott Col, Philadelphia, pp 183–200.Google Scholar
  2. 2.
    D. Machover, I Schwarzenberg, et al, Treatment of Advanced Colorectal and Gastric Adenocarcinoma With 5-FU Combined With High-Dose Folinic Acid: A Pilot Study, Cancer Treat Rep, 66: 1803–1807.Google Scholar
  3. 3.
    S. Waxman, H. Buckner, The Enchancement of 5-Fluorouracil Anti-Metabolic Activity by Leucovorin, Menadione, and a Tocopherol, Eur J Cancer Clin Oncol, 18: 685–692, 1982.PubMedCrossRefGoogle Scholar
  4. 4.
    C. J. Allegra, B. A. Chabner, P. W. Sholar, et al, Preliminary Results of a Phase II Trial for the Treatment of Metastatic Breast Cancer With 5-Fluorouracil and Leucovorin, NCI Monogr 5: 199–202, 1987.PubMedGoogle Scholar
  5. 5.
    M. A. Poon, M. J. O’Connell, H. S. Wieand, et al, Biochemical Modulation of Fluorouracil, Evidence of Significant Improvement of Survival and Quality of Life in Advanced Colorectal Carcinoma, (in preparation).Google Scholar
  6. 6.
    G. Marini, E. Simoncini, A. Zaniboni, et al, 5-Fluorouracil and High-Dose Folinic Acid as Salvage Treatment of Advanced Breast Cancer: An Update, Oncology, 44: 336–340, 1987.PubMedCrossRefGoogle Scholar
  7. 7.
    J. Doroshow, M. Bertrand, P. Multhauf, et al, High Dose Continuous Infusion Folinic Acid (HDFA) and IV Bolus 5-FU: An Effective Salvage Regimen for Refractory Metastatic Breast Cancer, Proc Am Soc Clin Oncol, 5: 65, 1986.Google Scholar
  8. 8.
    J. L. Grem, D. F. Hoth, M. Hamilton, et al, Overview of Current Status and Future Direction of Clinical Trials With 5-Fluorouracil in Combination With Folinic Acid, Cancer Treat Rep, 71: 1249–1264, 1987.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • C. L. Loprinzi
    • 1
  • J. N. Ingle
    • 1
  • D. J. Schaid
    • 1
  • J. C. Buckner
    • 1
  • J. H. Edmonson
    • 1
  1. 1.Divisions of Medical Oncology and Cancer Center StatisticsMayo ClinicRochesterUSA

Personalised recommendations